On a fall afternoon, John Bishop, the CEO of Cepheid, a company that develops genetics-based analysis systems for clinical diagnosis and biothreat assessment, pulls a piece of paper from behind the desk of his sparsely decorated Sunnyvale, Calif., office. On the paper - which Bishop holds perhaps more dear than anything else in his office - are bar graphs displaying the personality attributes of his key employees.
Advertisement
Survey Series
Institutions
For Advertisers
Communicating Success
Cepheid CEO John Bishop, a biotech veteran of nearly 40 years, guides his company into the next wave of clinical diagnostics.
For FREE access to this article and more, you must register.
|
|||||||||
|
